feed,title,long_url,short_url
BioRxiv,Targeting SARS-CoV-2 infection through CAR T cells and bispecific T cell engagers,https://biorxiv.org/cgi/content/short/2022.01.19.476940v1?rss=1,https://bit.ly/3FPHv9g
BioRxiv,Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response,https://biorxiv.org/cgi/content/short/2022.01.20.476754v1?rss=1,https://bit.ly/3KvIfnz
BioRxiv,Evidence of antibodies against SARS-CoV-2 in wild mustelids from Brittany (France),https://biorxiv.org/cgi/content/short/2022.01.20.477038v1?rss=1,https://bit.ly/3fMhVaG
BioRxiv,"Longitudinal Assessment of SARS-CoV-2 Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multi-Cytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity",https://biorxiv.org/cgi/content/short/2022.01.18.476864v1?rss=1,https://bit.ly/3AgQUpr
